Scholarlink

Introduction <p>The OVOC study was carried out to evaluate the management and clinical evolution of patients with advanced ovarian cancer (AOC) in routine clinical practice in Spain.</p> Methods <p>A retrospective study was made in women diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO IIIB-IV) who had received at least one line of treatment between 2013 and 2016, before the establishment of poly ADP ribose polymerase (PARP) inhibitors as first-line treatment.</p> Results <p>A total of 400 patients (median age: 61.7&#xa0;years; FIGO IIIC: 60.0%; high-grade serous carcinoma: 75.0%) received a median of two therapy lines. Primary and interval debulking surgery was performed in 37.0% and 54.3% of the patients. Germline <i>BRCA1</i> and <i>BRCA2</i> mutations were found in 16.2% and 12.0% of the patients. The median progression-free survival (PFS) from the start of the first-/second-/third-line of treatment was 14.2/8.7/4.5&#xa0;months. The median treatment-free interval (TFI) to the start of the second line was 9.9&#xa0;months. The median overall survival (OS) was 42.6&#xa0;months. At first relapse, 65.9% of the patients were platinum-sensitive and 34.1% platinum-resistant. Biologic therapies were administered in 25.2% of the platinum-sensitive and 16.2% of the platinum-resistant patients. Patients harboring <i>BRCA</i> mutations had a lower risk of progression/relapse after the first (<i>BRCA1</i> and <i>BRCA2</i> mutation versus native: <i>p</i> &lt; 0.0001) and second line (<i>BRCA1</i> and <i>BRCA2</i> mutation versus native: <i>p</i> = 0.021 and <i>p</i> = 0.037, respectively). Patients with <i>BRCA2</i> mutations had a lower mortality risk than those without (<i>p</i> = 0.015). The median PFS was significantly higher in patients receiving targeted therapy in the first (17.4 versus 11.6&#xa0;months; <i>p</i> = 0.039) and second line (11.1 versus 7.8&#xa0;months; <i>p</i> &lt; 0.001).</p> Conclusion <p>This study provides real-world data on therapeutic management and outcomes in AOC patients in Spain. A longer PFS was achieved in patients receiving targeted therapies. <i>BRCA1/2</i> mutations were a favorable prognostic factor for PFS and <i>BRCA2</i> mutation for OS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月20日

查看全文
  • Maria Quindós-Varela,
  • Diego Soto de Prado-Otero,
  • Alejandro Gallego,
  • Yolanda García,
  • Eva Guerra,
  • Purificación Estévez-García,
  • Maria Pilar Barretina-Ginesta,
  • Pilar Borraz,
  • Antonio González-Martín,
  • María Jesús Rubio

摘要

Introduction

The OVOC study was carried out to evaluate the management and clinical evolution of patients with advanced ovarian cancer (AOC) in routine clinical practice in Spain.

Methods

A retrospective study was made in women diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO IIIB-IV) who had received at least one line of treatment between 2013 and 2016, before the establishment of poly ADP ribose polymerase (PARP) inhibitors as first-line treatment.

Results

A total of 400 patients (median age: 61.7 years; FIGO IIIC: 60.0%; high-grade serous carcinoma: 75.0%) received a median of two therapy lines. Primary and interval debulking surgery was performed in 37.0% and 54.3% of the patients. Germline BRCA1 and BRCA2 mutations were found in 16.2% and 12.0% of the patients. The median progression-free survival (PFS) from the start of the first-/second-/third-line of treatment was 14.2/8.7/4.5 months. The median treatment-free interval (TFI) to the start of the second line was 9.9 months. The median overall survival (OS) was 42.6 months. At first relapse, 65.9% of the patients were platinum-sensitive and 34.1% platinum-resistant. Biologic therapies were administered in 25.2% of the platinum-sensitive and 16.2% of the platinum-resistant patients. Patients harboring BRCA mutations had a lower risk of progression/relapse after the first (BRCA1 and BRCA2 mutation versus native: p < 0.0001) and second line (BRCA1 and BRCA2 mutation versus native: p = 0.021 and p = 0.037, respectively). Patients with BRCA2 mutations had a lower mortality risk than those without (p = 0.015). The median PFS was significantly higher in patients receiving targeted therapy in the first (17.4 versus 11.6 months; p = 0.039) and second line (11.1 versus 7.8 months; p < 0.001).

Conclusion

This study provides real-world data on therapeutic management and outcomes in AOC patients in Spain. A longer PFS was achieved in patients receiving targeted therapies. BRCA1/2 mutations were a favorable prognostic factor for PFS and BRCA2 mutation for OS.